Cargando…

Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib

SIMPLE SUMMARY: ALK translocation is present in 4–5% of patients with non-small-cell lung cancer. Patients treated with alectinib invariably develop subclinical hemolysis, which is presumably caused by acanthocytic deformation and splenic trapping of blood erythrocytes. Morphologic red blood cell ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kunz, Julia, Wiedemann, Christiane, Grosch, Heidrun, Kriegsmann, Katharina, Gryzik, Stefanie, Felden, Julia, Hundemer, Michael, Seker-Cin, Huriye, Stenzinger, Miriam, Leo, Albrecht, Stenzinger, Albrecht, Thomas, Michael, Christopoulos, Petros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179520/ https://www.ncbi.nlm.nih.gov/pubmed/35681698 http://dx.doi.org/10.3390/cancers14112720

Ejemplares similares

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report
por: Wiedemann, Christiane, et al.
Publicado: (2022)

A case of extravascular hemolysis with Tk-activation
por: Yamada, Chisa, et al.
Publicado: (2014)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinib
por: Roeper, Julia, et al.
Publicado: (2022)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
por: Blasi, Miriam, et al.
Publicado: (2021)

Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis
por: Blasi, Miriam, et al.
Publicado: (2022)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Acanthocytosis and HyperCKemia
por: Yiş, Uluç, et al.
Publicado: (2018)

Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples
por: Kriegsmann, Katharina, et al.
Publicado: (2021)

McLeod syndrome and acanthocytosis
por: Mehndiratta, M.
Publicado: (2011)

Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma
por: Fisch, David, et al.
Publicado: (2021)

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
por: Neumann, Olaf, et al.
Publicado: (2022)

Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes
por: Kriegsmann, Mark, et al.
Publicado: (2020)

Chorea-acanthocytosis: a case report
por: Thapa, Lekhjung, et al.
Publicado: (2016)

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
por: Kriegsmann, Mark, et al.
Publicado: (2014)

Molecular driver alterations and their clinical relevance in cancer of unknown primary site
por: Löffler, Harald, et al.
Publicado: (2016)

Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer
por: Kazdal, Daniel, et al.
Publicado: (2017)

Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report
por: Ball, Markus, et al.
Publicado: (2022)

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
por: Niehr, Franziska, et al.
Publicado: (2015)

The combinatorial complexity of cancer precision medicine
por: Klauschen, Frederick, et al.
Publicado: (2014)

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
por: Budczies, Jan, et al.
Publicado: (2017)

A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer
por: Bozorgmehr, Farastuk, et al.
Publicado: (2021)

Cellular dissociation grading on biopsies of pulmonary squamous cell carcinoma provides prognostic information across all stages and is congruent with resection specimen grading
por: Jesinghaus, Moritz, et al.
Publicado: (2022)

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
por: Kirchner, M., et al.
Publicado: (2021)

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial
por: Christopoulos, Petros, et al.
Publicado: (2021)

Chorea–Acanthocytosis and the Huntington Disease Allele in an Irish Family
por: Murphy, Olwen C., et al.
Publicado: (2018)

Axial Sensory Tricks in Chorea–Acanthocytosis: Insights into Phenomenology
por: Bhidayasiri, Roongroj, et al.
Publicado: (2017)

Two case reports of chorea-acanthocytosis and review of literature
por: Huang, Shuangfeng, et al.
Publicado: (2022)

Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis
por: Peikert, Kevin, et al.
Publicado: (2021)

Chorea‐Acanthocytosis Presenting with Parkinsonism‐Dystonia without Chorea
por: Monfrini, Edoardo, et al.
Publicado: (2023)

Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data
por: Budczies, Jan, et al.
Publicado: (2018)

Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy
por: Kriegsmann, Mark, et al.
Publicado: (2020)

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
por: Rheinheimer, Stephan, et al.
Publicado: (2020)

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
por: Daniello, Lea, et al.
Publicado: (2021)

Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis
por: Romanovsky, Eva, et al.
Publicado: (2023)

Facial cellulitis revealing choreo-acanthocytosis: a case report
por: Samia, Younes, et al.
Publicado: (2014)

Globus Pallidus Interna Deep Brain Stimulation for Chorea-Acanthocytosis
por: Lee, Jae-Hyeok, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lj0i88kv8dptvdabgjr8oaomah